Department of Orthopedics, Shenzhen Intelligent Orthopaedics and Biomedical Innovation Platform, Guangdong Artificial Intelligence Biomedical Innovation Platform, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Department of Chemistry, The Chinese University of Hong Kong, Shatin, China.
J Drug Target. 2021 Jul;29(6):609-616. doi: 10.1080/1061186X.2020.1870231. Epub 2021 Feb 22.
Osteoarthritis (OA）is a common orthopaedic disease in middle-aged and aged people. To date, no disease-modifying drug is available to prevent the progression of OA. Surgical treatment of OA has complications such as pain and high costs with increased risk of post-operative infections. An intra-articular drug delivery is a conservative treatment method to apply therapeutic composites directly into the OA joint cavity. This method has an advantage to improve the bioavailability of therapeutics and hence is a widely preferred choice to test novel disease-modifying drug targets for OA. Herein, we summarised and discussed the current status of intra-articular therapy for OA treatment as well as outlined drug delivery of small molecular, protein and gene delivery for OA therapy. Currently, new targeted nano-based drug delivery systems, including nanoparticles, exosomes and hydrogel formulations under investigation for OA treatment intra-articular injection are also addressed. The emerging trend demonstrates that intra-articular drug delivery has vast prospects for the clinical selective treatment of OA. The rational application of intra-articular injection of drugs and biological agents will be of great significance for alleviating the patients with OA, improving their quality of life, delaying surgery, and reducing the disease burden of OA.
骨关节炎（OA）是中老年人常见的骨科疾病。迄今为止，尚无能够预防 OA 进展的疾病修饰药物。OA 的手术治疗存在疼痛和成本高的并发症，并且术后感染的风险增加。关节内药物输送是一种将治疗性复合材料直接应用于 OA 关节腔的保守治疗方法。这种方法具有提高治疗剂生物利用度的优势，因此是测试 OA 新型疾病修饰药物靶点的广泛首选方法。本文总结和讨论了 OA 治疗的关节内治疗现状，并概述了小分子、蛋白质和基因治疗 OA 的药物输送。目前，正在研究针对 OA 治疗的新型靶向纳米药物输送系统，包括关节内注射的纳米颗粒、外泌体和水凝胶制剂。新出现的趋势表明，关节内药物输送具有治疗 OA 的广阔前景。合理应用关节内注射药物和生物制剂将对缓解 OA 患者的病情、提高生活质量、延缓手术和减轻 OA 的疾病负担具有重要意义。
